Apyx Medical delivered a cleaner bottom line than Wall Street expected in the third quarter, but the top line raises a harder question. The company lost $0.04 per share, beating the consensus estimate of a $0.07 loss by 42.9%. That is a 20.0% year-over-year improvement in per-share results. Revenue of $14.03 million topped the $13.63 million consensus by 2.9% and grew 9.0% year over year. The profitability story is improving, while revenue growth is slowing quickly. That is the central tension.

The quality of the earnings improvement is real, though modest in absolute terms. On a GAAP basis, net loss attributable to stockholders narrowed to $1.8 million from $2.0 million. Operating loss shrank to $0.6 million from $0.8 million. Adjusted EBITDA swung to a $0.4 million profit from a $0.1 million loss a year ago and a $0.7 million loss in the second quarter. Management highlighted that trailing-twelve-month EBITDA has now turned positive.

Gross margin held essentially steady at 64.2%. Operating cash burn fell to $1.6 million from $3.5 million in the second quarter. Investors should note two caveats:

• The adjusted EBITDA figure adds back $0.75 million in stock-based compensation, up from $0.53 million a year ago.
• Interest expense of roughly $1.4 million a quarter on about $35.6 million of long-term debt still keeps GAAP results firmly in the red.

The deceleration is the bigger story. Total revenue growth has stepped down from +35% in the fourth quarter of 2025 to +32%, +22%, and now +9%. Surgical Aesthetics grew 17%, down from 28%, 36%, and 38% over the prior three quarters. Domestic sales rose just 4%, compared with 21% in the second quarter. Part of this is mechanical, because AYON launched in the third quarter of 2025 and the company is now lapping that launch. Still, the release also disclosed lower domestic sales of standalone generators and lower global sales of single-use handpieces. OEM revenue fell 41.5% to $1.1 million as the company deprioritizes that segment. International sales were the bright spot, up 22% on Renuvion generator sales, with the call crediting the Korea launch.

Guidance reinforces the split between margins and growth. Apyx reaffirmed full-year revenue guidance of $59.0 million to $60.0 million. It also lowered its operating-expense outlook to $41.0 million to $42.5 million from a prior ceiling of under $45.0 million. On gross margin, the sources disagree:

• The press release states a 63% to 65% range.
• The call analysis cites a raise to 63%–64%, up from 62%–63% earlier in the year.

Either way, the margin outlook moved higher. The revenue math is less flattering. The reaffirmed range implies fourth-quarter revenue of roughly $18.6 million to $19.6 million, about flat against $19.2 million a year ago. Management attributed this to the tough comparison against last year's compressed AYON shipments.

The call did preserve a credible set of growth catalysts:

• The power liposuction handpiece backlog was fully cleared by quarter-end, so new AYON buyers can now receive the handpiece at purchase. Management estimates about 70% of plastic surgeons use power liposuction.
• New customers rose to roughly 25% of AYON sales, up from about 20% earlier in the year.
• A new peer-reviewed study gives Renuvion a skin-quality angle. The sample was small, with six participants completing follow-up.
• Management flagged reconstructive and hospital markets as opportunities for AYON.

Bears have legitimate ammunition on liquidity. Cash fell to $25.8 million from $27.6 million at mid-year and $31.7 million at year-end. Stockholders' equity shrank to $9.6 million. Inventory climbed to $12.0 million from $8.6 million. Earlier statements about liquidity lasting into 2028 and reaching cash-flow-positive status by the fourth quarter were not reiterated. Management also gave no timeline for international AYON registrations.

The market setup is more complicated than the beat implies. Investor sentiment heading into the report became notably more positive, rising about 0.29 points from the prior report to the top of the scale. Yet the stock has moved hard in the opposite direction. Shares sat at $2.59 on the eve of the release, down 37.7% from the $4.16 open following the August report. That leaves them about 28% below the 200-day moving average of $3.58. The stock set a 52-week low of $2.25 on October 23 and has bounced only about 15% from that level. It remains roughly 39% below the inter-earnings high of $4.25, which was set the day after the last report. Price trend and AVWAP readings remain negative, consistent with a stock that has been sold steadily despite upbeat sentiment.

The bottom line is that Apyx is executing on cost control and margins, with positive adjusted EBITDA, lower expense guidance, and reduced cash burn. However, its growth engine is visibly downshifting, and guidance implies a flat fourth quarter. The power liposuction rollout and rising new-customer mix offer a path to reacceleration in 2027. Until revenue growth turns back up and management restores clearer cash-runway commitments, the beat does more to stabilize the story than to reverse the market's skepticism.